MASSACHUSETTS GENERAL HOSPITAL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
2.4k
Trial Phases
6 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (2039 trials with phase data)• Click on a phase to view related trials
Finding Links Between Hot flASHes and CardioVascular Disease
- Conditions
- Menopause-related Hot Flashes
- Interventions
- Drug: placebo
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT07077395
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC)ccRCC
- Interventions
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT07077083
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Telehealth in an Ambulatory Oncology Phase I Clinical Trial Unit
- Conditions
- Malignant Neoplasm
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT07069868
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
- Conditions
- Stomach Cancer Stage IVEsophagus CancerStomach Cancer
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07070466
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Effect of Mindfulness-based Neurofeedback for Adolescents With Elevated Repetitive Negative Thinking
- Conditions
- Repetitive Negative ThinkingNeurofeedback
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07055217
- Locations
- 🇺🇸
Massachusetts General Hospital, Center for Addiction Medicine, 101 Merrimac Street, Suite 320, Boston, MA 02114, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 486
- Next
News
GLP-1 Receptor Agonists Naturally Restore Testosterone Levels in Men with Obesity and Type 2 Diabetes
A retrospective study of 110 men with obesity or Type 2 diabetes found that GLP-1 receptor agonists like semaglutide and tirzepatide can naturally restore testosterone levels over 18 months of treatment.
UAEU Researcher Secures Four Patents for Computational Drug Design and Medical Device Innovations
Dr. Alya A. Arabi from United Arab Emirates University has been granted four patents spanning computational drug design and medical device development.
Novel Royalty-Based Investment Fund Proposes New Model for ALS Drug Development
Researchers from MIT, Massachusetts General Hospital, and Boston University propose a novel "Fund of Adaptive Royalties" (FAR) that finances half the cost of adaptive platform trials in exchange for future drug royalties.
Duvelisib-Romidepsin Combination Shows 61% Response Rate in Relapsed T-Cell Lymphomas
A real-world study by Mass General Brigham's PETAL Consortium demonstrated that the combination of duvelisib and romidepsin achieved a 61% overall response rate in 38 patients with relapsed/refractory T-cell lymphomas.
Alzamend Neuro Completes $5 Million Financing to Advance Five Phase II Trials for AL001 Lithium Therapy
Alzamend Neuro completed a $5 million private placement months ahead of schedule to fund five Phase II clinical trials of AL001 "Lithium in Brain" studies at Massachusetts General Hospital.
Penumbra Completes Enrollment in Landmark STORM-PE Trial Testing Thrombectomy for Pulmonary Embolism
Penumbra has completed enrollment of 100 patients in the pivotal STORM-PE randomized controlled trial, comparing computer assisted vacuum thrombectomy plus anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism.
Fidaxomicin Demonstrates Superior Efficacy in Reducing C. difficile Recurrence Among High-Risk Patients
Multiple studies presented at MAD-ID 2025 demonstrate fidaxomicin's superior efficacy over vancomycin in preventing C. difficile infection recurrence among high-risk patient populations.
Psilocybin Clinical Trial Targets Treatment-Resistant IBS in Groundbreaking Gastroenterology Study
Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS).
TPN-101 Selected for HEALEY ALS Platform Trial Following Promising Phase 2 Results in C9orf72-Related ALS
TPN-101, a first-in-class LINE-1 reverse transcriptase inhibitor, has been selected for inclusion in the Phase 2/3 HEALEY ALS Platform Trial based on promising Phase 2 data.
PSMA PET Imaging Transforms Prostate Cancer Management with Multiple FDA-Approved Agents
PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18.